
There is a growing trend in big pharma to talk up the potential for digital technology to revolutionise operations and …

With the retirement of Elias Zerhouni as Head of Global R&D, Sanofi had to find a suitable replacement and believes …

From March onwards, Takeda has been nudging a deal with Shire onwards through repeatedly improved offers, which has seen the …

FDA’s advisory committee were openly conflicted about deciding on the safety of Eli Lilly and Incyte’s drug, baricitinib, for the …

AstraZeneca has been hit by a fresh blow in its search for an immunotherapy combination treatment that could differentiate it …

Shares in Prothena have dropped by close to 70% on the news that two of its trials into its lead …

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …

After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

After the FDA advisory committee unanimously recommended GW Pharma’s Epidiolex for approval, the chances of it not receiving the nod …

Allergan performed an odd about-turn after initially declaring its interest in pursuing a deal for Shire, before reneging on that …

BenevolentAI, a London based drug discovery biotech, has revealed that a $115 million financing round now sees the company valued …

Merck KGaA has successfully found a buyer for its healthcare unit, after Proctor & Gamble announced that it was prepared …

The first stage of separation for the EMA from the UK came with the decision to relocate its headquarters to …

Manufacturing issues at the single Pfizer plant that produces the EpiPen epinephrine injector has caused serious shortages in the UK …